TScan Therapeutics Announces Launch of Proposed Public Offering
25 mai 2023 16h06 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
24 mai 2023 16h13 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX) (TScan), a clinical-stage biopharmaceutical company focused on the development of T cell receptor...
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
17 mai 2023 07h00 HE
|
TScan Therapeutics, Inc.
Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation Company to host a virtual KOL event featuring Monzr M. Al Malki, M.D., to...
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
10 mai 2023 07h00 HE
|
TScan Therapeutics, Inc.
Entered into partnership with Amgen to identify novel targets in Crohn’s disease; TScan to receive $30 million upfront Enrolled patients in all three arms of Phase 1 hematologic malignancies study;...
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
09 mai 2023 09h00 HE
|
TScan Therapeutics, Inc.
Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With...
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
02 mai 2023 16h42 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
10 avr. 2023 07h00 HE
|
TScan Therapeutics, Inc.
Deepens the Board’s clinical oncology and commercialization expertise as programs for hematologic malignancies and solid tumors advance Company also announces key leadership promotions WALTHAM,...
TScan Therapeutics Announces CEO Transition
31 mars 2023 08h00 HE
|
TScan Therapeutics, Inc.
David Southwell steps down; Gavin MacBeath, Ph.D., Chief Scientific and Operating Officer, to serve as acting CEO Company reaffirms previously disclosed milestones and cash runway; provides clinical...
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
14 mars 2023 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
13 mars 2023 16h05 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...